Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Crack, Peter J ^a   Zhang, Moses ^a   Morganti Kossmann, Maria C ^b,c   Morris, Andrew J ^d   Wojciak, Jonathan M ^e   Fleming, Jonathan K ^e   Karve, Ila ^a   Wright, David ^a,f   Sashindranath, Maithili ^b   Goldshmit, Yona ^a,g   Conquest, Alison ^a,b   Daglas, Maria ^b   Johnston, Leigh A ^a,f   Medcalf, Robert L ^b   Sabbadini, Roger A ^e   Pébay, Alice ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e SAN DIEGO STATE UNIVERSITY   (United States)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^g Monash University   (Australia)

Author keywords

Anti LPA antibody; Control cortical impact; Human cerebrospinal fluid; IL 6; Lysophosphatidic acid; Magnetic resonance imaging; Traumatic brain injury

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; LPATHOMAB;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOLOGY; HUMAN; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TISSUE INJURY; TRAUMATIC BRAIN INJURY; YOUNG ADULT; ANIMAL BEHAVIOR; ANIMAL TISSUE; BRAIN SIZE; CEREBROSPINAL FLUID EXAMINATION; CONTUSION; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ADULT; AGED, 80 AND OVER; ANIMALS; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GLASGOW COMA SCALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84899476317     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-37     Document Type: Article

References (26)

1. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen RL. Early management of severe traumatic brain injury. Lancet 2012, 380:1088-1098. 10.1016/S0140-6736(12)60864-2, 22998718.
2. Frisca F, Sabbadini RA, Goldshmit Y, Pebay A. Biological effects of lysophosphatidic acid in the nervous system. Int Rev Cell Mol Biol 2012, 296:273-322.
3. Frugier T, Crombie D, Conquest A, Tjhong F, Taylor C, Kulkarni T, McLean C, Pebay A. Modulation of LPA receptor expression in the human brain following neurotrauma. Cell Mol Neurobiol 2011, 31:569-577. 10.1007/s10571-011-9650-0, 21234797.
4. Goldshmit Y, Bourne J. Upregulation of EphA4 on astrocytes potentially mediates astrocytic gliosis after cortical lesion in the marmoset monkey. J Neurotrauma 2010, 27:1321-1332. 10.1089/neu.2010.1294, 20486805.
5. Goldshmit Y, Matteo R, Sztal T, Ellett F, Frisca F, Moreno K, Crombie D, Lieschke GJ, Currie PD, Sabbadini RA, Pebay A. Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes. Am J Pathol 2012, 181:978-992. 10.1016/j.ajpath.2012.06.007, 3432439, 22819724.
6. Seifman MA, Adamides AA, Nguyen PN, Vallance SA, Cooper DJ, Kossmann T, Rosenfeld JV, Morganti-Kossmann MC. Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray. J Cereb Blood Flow Metab 2008, 28:684-696. 10.1038/sj.jcbfm.9600603, 18183032.
7. Chi JH, Knudson MM, Vassar MJ, McCarthy MC, Shapiro MB, Mallet S, Holcroft JJ, Moncrief H, Noble J, Wisner D, Kaups KL, Bennick LD, Manley GT. Prehospital hypoxia affects outcome in patients with traumatic brain injury: a prospective multicenter study. J Trauma 2006, 61:1134-1141. 10.1097/01.ta.0000196644.64653.d8, 17099519.
8. Marshall LF, Marshall SB, Klauber MR, Van Berkum CM, Eisenberg H, Jane JA, Luerssen TG, Marmarou A, Foulkes MA. The diagnosis of head injury requires a classification based on computed axial tomography. J Neurotrauma 1992, 9(Suppl 1):S287-S292.
9. Baker SP, O'Neill B, Haddon W, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974, 14:187-196. 10.1097/00005373-197403000-00001, 4814394.
10. Federico L, Ren H, Mueller PA, Wu T, Liu S, Popovic J, Blalock EM, Sunkara M, Ovaa H, Albers HM, Mills GB, Morris AJ, Smyth SS. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 2012, 26:786-797. 10.1210/me.2011-1229, 3355557, 22474126.
11. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods 1991, 39:253-262. 10.1016/0165-0270(91)90104-8, 1787745.
12. Sashindranath M, Sales E, Daglas M, Freeman R, Samson AL, Cops EJ, Beckham S, Galle A, McLean C, Morganti-Kossmann C, Rosenfeld JV, Madani R, Vassalli JD, Su EJ, Lawrence DA, Medcalf RL. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012, 135:3251-3264. 10.1093/brain/aws178, 3501968, 22822039.
13. Sashindranath M, Samson AL, Downes CE, Crack PJ, Lawrence AJ, Li QX, Ng AQ, Jones NC, Farrugia JJ, Abdella E, Vassalli JD, Madani R, Medcalf RL. Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Invest 2011, 91:1079-1091. 10.1038/labinvest.2011.67, 21519332.
14. Rasouli J, Lekhraj R, White NM, Flamm ES, Pilla AA, Strauch B, Casper D. Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury. Neurosci Lett 2012, 519:4-8. 10.1016/j.neulet.2012.03.089, 22503903.
15. Yang SH, Gangidine M, Pritts TA, Goodman MD, Lentsch AB. Interleukin 6 mediates neuroinflammation and motor coordination deficits after mild traumatic brain injury and brief hypoxia in mice. Shock 2013, 40:471-475. 10.1097/SHK.0000000000000037, 24088994.
16. Minambres E, Cemborain A, Sanchez-Velasco P, Gandarillas M, Diaz-Reganon G, Sanchez-Gonzalez U, Leyva-Cobian F. Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injury. Critical Care Med 2003, 31:933-938.
17. Hergenroeder GW, Moore AN, McCoy JP, Samsel L, Ward NH, Clifton GL, Dash PK. Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflam 2010, 7:19.
18. Koike S, Keino-Masu K, Ohto T, Masu M. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells 2006, 11:133-142. 10.1111/j.1365-2443.2006.00924.x, 16436050.
19. Boutin JA, Ferry G. Autotaxin. Cell Mol Life Sci 2009, 66:3009-3021. 10.1007/s00018-009-0056-9, 19506801.
20. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022. 10.1128/MCB.02419-05, 1489177, 16782887.
21. On NH, Savant S, Toews M, Miller DW. Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid. J Cereb Blood Flow Metabol 1944-1954, 2013:33.
22. Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, Aziat F, Wishart DS. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med 2012, 4:38. 10.1186/gm337, 3446266, 22546835.
23. Nakamura K, Kishimoto T, Ohkawa R, Okubo S, Tozuka M, Yokota H, Ikeda H, Ohshima N, Mizuno K, Yatomi Y. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Analyt Biochem 2007, 367:20-27. 10.1016/j.ab.2007.05.004, 17568554.
24. Darling RJ, Brault PA. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol 2004, 2:647-657. 10.1089/adt.2004.2.647, 15674023.
25. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A, Tigyi G. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J Biol Chem 2005, 280:35038-35050. 10.1074/jbc.M504351200, 16115890.
26. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, Shimizu T, Ishii S. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biolog Chem 2009, 284:17731-17741.